4De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome[J] .Am J Med Genet, 1996,62(4) :417-426.
5Robinson PN, Booms P, Katzke S, et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies[ J]. Hum Mutat,2002,20(3) : 153-161.
6Blobe GC, Sehiermann WP, Lodish HF. Role of transforming growth factor beta in human disease[J]. N Engl J Med,2000,342(18) : 1350- 1358.
7Del Re E, Babitt JL, Pirani A, et al. In the absence of type Ⅲ receptor, the transforming growth factor (TGF)-beta type Ⅱ-B receptor requires the type Ⅰ receptor to bind TGF-beta2 [ J ]. J Biol Chem, 2004,279 (21) :22765-22772.
8Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation[J] .J Cell Sci,2003,116(2):217-224.
9Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein[J] .J Biol Chem,2003,278(4 ) :2750-2757.
10Pereira L, Lee SY, Gayraud B, et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1 [J]. Proc Natl Acad Sci USA, 1999,96(7) :3819-3823.
